Lux Capital – Spring 2014

I had some very “emacerated” tissue below and I think it’s a pretty bad break out – so they put me on some pain meds, anti-itch meds and ran more tests. GEN-004 is an investigational vaccine candidate designed to prevent infections from all serotypes of pneumococcus (Streptococcus pneumoniae). As colonization is known to be the necessary precursor to infection by pneumococcus, this study could affirm the potential for GEN-004 to control infections caused by pneumococcus. Expanded management team with appointment of Jonathan Poole as chief financial officer. The company is now trying to raise a similar amount on the public markets, which put around $3 billion into newly-public biotechs in 2013. Genocea is able to identify protective T cell antigens in humans using ATLAS™, its proprietary technology platform, potentially enabling vaccines and immunotherapies to address critical patient needs. Genocea’s pipeline of novel T cell vaccines includes GEN-003 for HSV-2 therapy, GEN-004, and earlier-stage programs in chlamydia, HSV-2 prophylaxis and malaria.

Genocea is able to identify protective T cell antigens in humans using ATLAS™, its proprietary technology platform, potentially enabling vaccines and immunotherapies to address critical patient needs. Genocea intends to explore additional dose combinations in its upcoming Phase 2 dose optimization study, which may identify a dose which further improves the magnitude or durability of effect of GEN-003. Using ATLAS™, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. … The study enrolled over 300 subjects at 17 institutions in the United States. Genocea’s pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for HSV-2 therapy, GEN-004 to prevent infections caused by pneumococcus, and earlier-stage programs in chlamydia, HSV-2 prophylaxis, malaria and cancer immunotherapy. Using ATLAS™, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs.


GEN-003 also elicited T cell, IgG, and neutralizing antibody responses that remained significantly above baseline for 12 months. The Phase 1 study was a randomized, double-blind, dose-escalation, placebo-controlled clinical trial that enrolled 90 healthy adult volunteers. 99.1                         Press Release of Genocea Biosciences, Inc. In September 2014, Genocea received a $1.2 million grant from the Gates Foundation for the identification of protective T cell antigens for malaria vaccines, extending the collaboration through 2015. Genocea is able to identify protective T cell antigens in humans using ATLAS™, its proprietary technology platform, potentially enabling vaccines and immunotherapies to address critical patient needs. The Phase 1/2a clinical trial was a double-blind, placebo-controlled, dose-escalation study to evaluate the safety and immunogenicity of GEN-003. In the United States roughly 15 percent of the adult population, or 40 million people, are infected.

As colonization is known to be the necessary precursor to infection by pneumococcus, this study could affirm the potential for GEN-004 to control infections caused by pneumococcus. A focus is on the Sirtuin genes and how they protect against aging and diseases such as infection, cancer, heart disease, inflammation, neurodegeneration and diabetes. (NYSE: HTGC) (“Hercules”) is the leading specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related markets, including technology, biotechnology, life science, and energy & renewable technology industries, at all stages of development. You can get it on your lips from a chaste family member kiss. You’ll quickly discover why many people are choosing the Natural Healing College for their Holistic Education. This has become my favorite type of yoga and it’s very similar to hatha. Mercola “Fluzone High-Dose” is a new influenza vaccine manufactured by Sanofi Pasteur.

A Phase 2 dose optimization study is currently ongoing. GEN-003 is a first-in-class T cell vaccine candidate intended to reduce the transmission risk and clinical symptoms of HSV-2 by inducing a balanced B cell (antibody) and T cell immune response which is believed to be critical to achieving a long-term control of HSV-2. GEN-003 also elicited T cell, IgG, and neutralizing antibody responses that remained significantly above baseline for 12 months. Genocea, a company pioneering novel T cell vaccines and immunotherapies, reported the results from the ongoing trial of GEN-003 today as an oral presentation at the World Vaccine Congress, being held March 24-26 in Washington, DC. Now Knipe and his colleagues have shown that compounds that block this crucial step in HIV infection also prevent genital herpes and other herpes virus infections from taking hold. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today reported recent corporate highlights and financial results for the fourth quarter and year ended December 31, 2014. The Phase 1 study met its safety, tolerability and immunogenicity goals, including measurable increases in the blood of T helper 17 (TH17) cells, a rare cell type that provides immunity at epithelial and mucosal surfaces.

(NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced today that it will hold a conference call and live audio webcast on May 6, 2014 at 9:00 a.m.